Recent Posts

  • Yep. PIP while over goal, ghosted by GSK Mgr and gone. Talk about toxic!

anonymous
Feb 06, 2025 at 03:35 PM
  • Fast forward to July 4, 2025.
    Entresto has a biosimiliar, so half the C.V. sales force is gone.
    Lp(a) has taken a significant delay, and won't launch until middle 2027.
    C.V. is left with an appallingly mismanaged Leqvio to keep the division afloat for two years.
    Does Novartis eventually punt on C.V.?
    Look at the pipeline, what is coming that inspires confidence?
    Furthermore, they are too self-important to recognize it, but they clearly do not know what they are doing in the C.V. space, as they have destroyed their s.i.RNA and they are already off and running when it comes to destroying their ASO.
    Entresto? O.K., but don't forget how they struggled with it in the beginning.
    It probably won't happen, but it shouldn't come as a shock if they eventually move to three T.A.'s (maybe find a new home for renal) or find something to take the place of cardiovascular as a fourth pillar.
    Agree with most of what you say. Probably 30-40% of CV gone by end of summer. Definitely feels like Pelacarsen won't launch until 2027. At some point they will have to sell off or just give up on Leqvio. Not sure if they can write off the bad investment of purchasing Medicines Co. Maybe CRM with just become Renal.

anonymous
Feb 06, 2025 at 03:32 PM
  • Clam chowder is nice. New England, Manhattan...both a lovely treat.

anonymous
Feb 06, 2025 at 03:28 PM
anonymous
Feb 06, 2025 at 03:15 PM
  • All the decisions Bea and her leadership team has made has Peggy's fingerprints all over it. We all know who really is controlling the FMT.
    Let's focus on the positive. My time at Roche has been a valuable lesson in leadership pitfalls (i.e. Joni's cronies, Rav's Ted Lasso quotes, Toby's MacDaddy of Medical, and Bea's CLEAR OUT the leaders.

    From ineffective DEI initiatives to poor communication and elitist behaviors, it's a case study in what not to do. Specifically, I've observed leaders prioritizing appearances over engagement, content and character over charisma, making decisions without transparency, and fostering a culture of exclusivity. I couldn't even differentiate which RATL was which; they seem like Bea-look-alikes

    I end with this thought: how does FMT act upon health equity when you can't maintain equitable hiring practices? Did the MSLs who applied for the RMD roles get any feedback? How did you remove barriers to promotion? Or is health equity just lip service

anonymous
Feb 06, 2025 at 03:14 PM